NASDAQ:XOMA - XOMA Stock Price, Price Target & More

$23.53 +0.21 (+0.90 %)

(As of 04/19/2018 04:00 PM ET)

Previous Close$23.32

Today's Range$22.85 - $23.78

52-Week Range$5.86 - $37.25

Volume73,942 shs

Average Volume173,917 shs

Market Capitalization$188.64 million

P/E Ratio24.01

Dividend YieldN/A

Beta3.05

About XOMA (NASDAQ:XOMA)

XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab. Its XOMA 358 is meant for long-acting treatment of hyperinsulinemic hypoglycemia. XOMA 129 is meant for rapid onset, short-acting treatment of severe acute hypoglycemia. XOMA 213 is a Phase II-ready product candidate targeting the prolactin receptor, as well as research-stage programs targeting the parathyroid receptor (PTH1R) and the adrenal corticotropic hormone (ACTH). Gevokizumab is a humanized monoclonal antibody with allosteric properties that has the potential to treat patients with a range of inflammatory diseases. Its technologies include Antibody Discovery Advanced Platform Technologies (ADAPT), ModulX and OptimX.

Receive XOMA News and Ratings via Email

Sign-up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

SymbolNASDAQ:XOMA

CUSIP98419J10

Webwww.xoma.com

Phone510-204-7200

Debt

Debt-to-Equity Ratio2.52%

Current Ratio5.96%

Quick Ratio5.96%

Price-To-Earnings

Trailing P/E Ratio24.01

Forward P/E Ratio-18.98

P/E GrowthN/A

Sales & Book Value

Annual Sales$52.69 million

Price / Sales3.72

Cash Flow$2.2094 per share

Price / Cash10.65

Book Value$0.71 per share

Price / Book33.14

Profitability

EPS (Most Recent Fiscal Year)$0.98

Net Income$14.59 million

Net Margins27.49%

Return on Equity-130.44%

Return on Assets46.59%

Miscellaneous

Employees12

Outstanding Shares8,330,000

How to Become a New Pot Stock Millionaire

XOMA (NASDAQ:XOMA) Frequently Asked Questions

What is XOMA's stock symbol?

XOMA trades on the NASDAQ under the ticker symbol "XOMA."

How were XOMA's earnings last quarter?

XOMA Co. (NASDAQ:XOMA) announced its earnings results on Wednesday, March, 7th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.35) by $0.19. The biotechnology company had revenue of $5.36 million for the quarter, compared to analyst estimates of $4.12 million. XOMA had a negative return on equity of 130.44% and a net margin of 27.49%. View XOMA's Earnings History.

When is XOMA's next earnings date?

XOMA is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for XOMA.

What price target have analysts set for XOMA?

2 equities research analysts have issued 1-year price objectives for XOMA's shares. Their predictions range from $33.00 to $49.00. On average, they expect XOMA's share price to reach $41.00 in the next year. View Analyst Ratings for XOMA.

Who are some of XOMA's key competitors?

Some companies that are related to XOMA include GTX (GTXI), Clearside Biomedical (CLSD), Dermira (DERM), Kadmon (KDMN), Merus (MRUS), Seres Therapeutics (MCRB), AVEO Pharmaceuticals (AVEO), Zymeworks (ZYME), Aquinox Pharmaceuticals (AQXP), Catalyst Biosciences (CBIO), BioSpecifics Technologies (BSTC), Celyad (CYAD), Arbutus Biopharma (ABUS), Avadel Pharmaceuticals (AVDL), Savara (SVRA), Selecta Biosciences (SELB), Syndax Pharmaceuticals (SNDX) and Minerva Neurosciences (NERV).

Has XOMA been receiving favorable news coverage?

Headlines about XOMA stock have been trending somewhat negative this week, Accern reports. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. XOMA earned a news sentiment score of -0.02 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 45.37 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.

How do I buy shares of XOMA?

Shares of XOMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is XOMA's stock price today?

One share of XOMA stock can currently be purchased for approximately $23.53.

How big of a company is XOMA?

XOMA has a market capitalization of $188.64 million and generates $52.69 million in revenue each year. The biotechnology company earns $14.59 million in net income (profit) each year or $0.98 on an earnings per share basis. XOMA employs 12 workers across the globe.

How can I contact XOMA?

XOMA's mailing address is 2910 SEVENTH ST, BERKELEY CA, 94710. The biotechnology company can be reached via phone at 510-204-7200 or via email at [email protected]

MarketBeat Community Rating for XOMA (XOMA)

Community Ranking:		2.6 out of 5 ( )
Outperform Votes:		275 (Vote Outperform)
Underperform Votes:		249 (Vote Underperform)
Total Votes:		524

MarketBeat's community ratings are surveys of what our community members think about XOMA and other stocks. Vote "Outperform" if you believe XOMA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XOMA will underperform the S&P 500 over the long term. You may vote once every thirty days.

XOMA (NASDAQ:XOMA) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

2 Wall Street analysts have issued ratings and price targets for XOMA in the last 12 months. Their average twelve-month price target is $41.00, suggesting that the stock has a possible upside of 74.25%. The high price target for XOMA is $49.00 and the low price target for XOMA is $33.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	3.00	3.00	2.67	2.50
Ratings Breakdown:	0 Sell Rating(s) 0 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$41.00	$41.00	$41.00	$28.50
Price Target Upside:	74.25% upside	86.36% upside	25.65% upside	29.31% upside

XOMA (NASDAQ:XOMA) Consensus Price Target History

Price Target History for XOMA (NASDAQ:XOMA)

XOMA (NASDAQ:XOMA) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
3/9/2018	HC Wainwright	Set Price Target	Buy	$49.00	High
12/19/2017	Wedbush	Reiterated Rating	Buy	$33.00	Low
2/1/2017	Cowen	Reiterated Rating	Hold		N/A
11/16/2016	Ladenburg Thalmann	Reiterated Rating	Neutral		N/A
8/5/2016	Jefferies Group	Reiterated Rating	Hold		N/A

(Data available from 4/19/2016 forward)

XOMA (NASDAQ:XOMA) Earnings History and Estimates Chart

Earnings by Quarter for XOMA (NASDAQ:XOMA)

XOMA (NASDAQ:XOMA) Earnings Estimates

2018 EPS Consensus Estimate: ($1.07)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	($0.15)	($0.15)	($0.15)
Q2 2018	1	($0.11)	($0.11)	($0.11)
Q3 2018	1	($0.54)	($0.54)	($0.54)
Q4 2018	1	($0.27)	($0.27)	($0.27)

XOMA (NASDAQ XOMA) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/8/2018
3/7/2018	Q4 2017	($0.35)	($0.16)	$4.12 million	$5.36 million	View	N/A
11/6/2017	Q3 2017	($0.81)	$1.98	$17.95 million	$36.18 million	View	N/A
8/8/2017	Q2 2017	$0.34	$0.21	$10.56 million	$10.89 million	View	N/A
5/9/2017	Q1 2017	($1.30)	($2.30)	$0.96 million	$0.26 million	View	N/A
3/16/2017	Q4 2016	($2.32)	($2.89)	$0.50 million	$0.50 million	View	N/A
11/9/2016	Q3	($2.40)	($2.08)	$1.29 million	$0.64 million	View	N/A
8/3/2016		($0.12)	($0.13)	$0.84 million	$0.40 million	View	N/A
5/4/2016		($0.12)	($0.07)	$1.17 million	$3.96 million	View	N/A
3/9/2016	Q415	($0.15)	$0.21	$4.01 million	$48.18 million	View	Listen
11/5/2015	Q315	($0.16)	($0.18)	$3.55 million	$2.10 million	View	Listen
8/6/2015	Q215	($0.18)	($0.20)	$4.38 million	$2.54 million	View	Listen
5/7/2015	Q115	($0.16)	($0.19)	$4.31 million	$2.65 million	View	Listen
3/11/2015	Q414	($0.14)	($0.12)	$10.70 million	$4.30 million	View	N/A
11/6/2014	Q314	($0.17)	($0.17)	$7.00 million	$5.10 million	View	N/A
8/7/2014	Q214	($0.21)	($0.17)	$5.32 million	$5.97 million	View	Listen
5/7/2014	Q114	($0.17)	($0.23)	$7.40 million	$3.41 million	View	N/A
3/4/2014	Q413	($0.19)	($0.55)	$7.92 million	$8.45 million	View	N/A
11/7/2013	Q313	($0.18)	($0.21)	$7.87 million	$6.31 million	View	N/A
8/7/2013	Q2 2013	($0.19)	($0.21)	$9.30 million	$7.20 million	View	N/A
5/8/2013	Q1 2013	($3.40)	($3.00)	$9.42 million	$9.45 million	View	N/A
3/12/2013	Q4 2012	($4.80)	($3.60)			View	N/A
11/7/2012	Q312	($0.21)	($0.39)	$11.69 million	$7.30 million	View	N/A
8/7/2012	Q2 2012	($4.40)	($4.60)			View	N/A
5/8/2012	Q1 2012	($5.20)	($5.54)			View	N/A
3/14/2012	Q4 2011	($5.00)	($6.82)			View	N/A
11/9/2011	Q3 2011	($6.40)	($4.00)			View	N/A
8/4/2011	Q2 2011	($4.80)	($5.44)			View	N/A
5/5/2011	Q1 2011	($8.80)	($4.34)			View	N/A
3/10/2011	Q4 2010	($14.60)	($16.76)			View	N/A
11/4/2010	Q3 2010	($16.80)	($13.76)			View	N/A
8/9/2010	Q2 2010	($20.99)	($18.59)			View	N/A
5/6/2010	Q1 2010	($17.99)	($27.29)			View	N/A
3/11/2010	Q4 2009	($9.00)	$4.50			View	N/A
11/9/2009	Q3 2009		$2.70			View	N/A
8/6/2009	Q2 2009	($26.99)	($19.79)			View	N/A
5/7/2009	Q1 2009	$3.00	$16.49			View	N/A
11/10/2008	Q3 2008	($26.99)	($46.18)			View	N/A
8/7/2008	Q2 2008	($29.99)	($46.78)			View	N/A
5/12/2008	Q1 2008	($17.99)	($32.08)			View	N/A
3/11/2008	Q4 2007	($32.98)	($20.99)			View	N/A

(Earnings results data provided by Zacks Investment Research)

XOMA (NASDAQ:XOMA) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

XOMA (NASDAQ XOMA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.90%
Institutional Ownership Percentage: 38.85%

Insider Trading History for XOMA (NASDAQ:XOMA)

Institutional Ownership by Quarter for XOMA (NASDAQ:XOMA)

XOMA (NASDAQ XOMA) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/15/2017	James R. Neal	CEO	Sell	46,296	$28.24	$1,307,399.04
11/15/2017	Thomas M Burns	SVP	Sell	22,222	$28.69	$637,549.18	13,538
11/13/2017	James R. Neal	CEO	Sell	11,568	$30.83	$356,641.44
11/13/2017	Thomas M Burns	CFO	Sell	6,983	$30.99	$216,403.17	13,538
5/16/2017	John Varian	Director	Sell	39,540	$6.24	$246,729.60	2,344
3/21/2017	James R. Neal	VP	Sell	5,105	$5.40	$27,567.00
2/1/2017	James R Neal	VP	Sell	195	$4.52	$881.40	20,566
1/9/2017	James R. Neal	VP	Sell	125	$5.15	$643.75
12/21/2016	John Varian	Director	Sell	13,549	$5.75	$77,906.75	41,884
12/21/2016	Patrick J Md Phd Scannon	VP	Sell	3,230	$5.75	$18,572.50	8,217
11/1/2016	James R. Neal	VP	Sell	150	$5.25	$787.50
10/7/2016	James R. Neal	VP	Sell	2,500	$0.45	$1,125.00
3/22/2016	John Varian	CEO	Sell	81,022	$0.78	$63,197.16	1,189,695
3/22/2016	Patrick J Md Phd Scannon	VP	Sell	14,785	$0.78	$11,532.30	243,727
3/22/2016	Paul D Rubin	CMO	Sell	24,194	$0.78	$18,871.32	350,795
2/1/2016	Patrick J Md Phd Scannon	VP	Sell	8,000	$1.01	$8,080.00	94,227
12/28/2015	Patrick J Md Phd Scannon	VP	Sell	8,000	$1.37	$10,960.00	102,227
11/23/2015	Patrick J Md Phd Scannon	VP	Sell	8,000	$1.35	$10,800.00	110,227
10/26/2015	Patrick J Md Phd Scannon	VP	Sell	8,000	$1.04	$8,320.00	118,227
7/22/2015	Bros. Advisors Lp Baker	Insider	Sell	11,000,000	$1.09	$11,990,000.00
7/15/2015	John Varian	CEO	Sell	10,000	$4.49	$44,900.00
7/15/2015	Paul D Rubin	CMO	Sell	5,000	$4.60	$23,000.00
7/10/2015	Paul D Rubin	CMO	Sell	33,400	$4.55	$151,970.00
6/15/2015	John Varian	CEO	Sell	10,000	$3.64	$36,400.00
4/15/2015	John Varian	CEO	Sell	10,000	$3.86	$38,600.00
3/23/2015	Paul D Rubin	CMO	Sell	32,742	$3.94	$129,003.48
3/16/2015	John Varian	CEO	Sell	10,000	$3.72	$37,200.00
2/2/2015	Patrick J Md Phd Scannon	VP	Sell	5,000	$3.52	$17,600.00
1/15/2015	John Varian	CEO	Sell	10,000	$3.46	$34,600.00
1/6/2015	Bros. Advisors Lp Baker	Director	Sell	2,215,400	$3.81	$8,440,674.00
1/2/2015	Patrick J Md Phd Scannon	VP	Sell	5,000	$3.55	$17,750.00
12/30/2014	Bros. Advisors Lp Baker	Director	Sell	744,000	$3.67	$2,730,480.00
12/19/2014	Bros. Advisors Lp Baker	Director	Sell	1,605,100	$4.26	$6,837,726.00
12/16/2014	Bros. Advisors Lp Baker	Director	Sell	1,033,800	$4.46	$4,610,748.00
12/15/2014	John Varian	CEO	Sell	10,000	$4.49	$44,900.00
12/15/2014	Paul D Rubin	CMO	Sell	1,600	$4.63	$7,408.00
12/9/2014	Bros. Advisors Lp Baker	Director	Sell	392,353	$4.62	$1,812,670.86
12/4/2014	Bros. Advisors Lp Baker	Director	Sell	2,372,206	$4.79	$11,362,866.74
12/1/2014	Patrick J Md Phd Scannon	VP	Sell	5,000	$5.51	$27,550.00
11/26/2014	James R Neal	VP	Sell	1,678	$5.67	$9,514.26
11/24/2014	James R Neal	VP	Sell	1,032	$5.03	$5,190.96
11/20/2014	Paul D Rubin	CMO	Sell	5,000	$4.55	$22,750.00
11/13/2014	Fred Kurland	CFO	Sell	8,773	$3.89	$34,126.97
11/13/2014	James R Neal	VP	Sell	4,387	$3.89	$17,065.43
11/13/2014	John Varian	CEO	Sell	58,844	$3.89	$228,903.16
11/3/2014	Patrick J Md Phd Scannon	VP	Sell	5,000	$4.33	$21,650.00
10/28/2014	Paul D Rubin	CMO	Sell	5,000	$4.57	$22,850.00
10/15/2014	John Varian	CEO	Sell	10,000	$3.87	$38,700.00
10/1/2014	Patrick J Md Phd Scannon	VP	Sell	5,000	$4.09	$20,450.00
9/15/2014	John Varian	CEO	Sell	10,000	$4.56	$45,600.00
9/15/2014	Paul D Rubin	CMO	Sell	5,000	$4.59	$22,950.00
9/4/2014	Paul D Rubin	CMO	Sell	10,000	$4.56	$45,600.00
9/2/2014	Patrick J Md Phd Scannon	VP	Sell	5,000	$4.31	$21,550.00
8/18/2014	Paul D Rubin	CMO	Sell	26,748	$4.34	$116,086.32
8/15/2014	Fred Kurland	CFO	Sell	10,401	$4.31	$44,828.31
8/15/2014	John Varian	CEO	Sell	64,823	$4.30	$278,738.90
8/15/2014	Patrick J Md Phd Scannon	VP	Sell	5,871	$4.31	$25,304.01
8/1/2014	Patrick J Md Phd Scannon	VP	Sell	5,000	$3.83	$19,150.00
7/15/2014	John Varian	CEO	Sell	10,000	$4.03	$40,300.00
7/1/2014	Patrick J Md Phd Scannon	VP	Sell	5,000	$4.68	$23,400.00
6/16/2014	John Varian	CEO	Sell	10,000	$4.54	$45,400.00
6/16/2014	Paul D Rubin	CMO	Sell	11,580	$4.54	$52,573.20
5/28/2014	Paul D Rubin	CMO	Sell	1,785	$4.22	$7,532.70
5/15/2014	John Varian	CEO	Sell	10,000	$3.55	$35,500.00	285,613
4/15/2014	John Varian	CEO	Sell	10,000	$4.06	$40,600.00	285,613
3/18/2014	Fred Kurland	CFO	Sell	5,915	$6.32	$37,382.80	62,600
3/18/2014	John Varian	CEO	Sell	21,329	$6.32	$134,799.28	285,613
3/18/2014	Patrick Md Phd Scannon	VP	Sell	3,419	$6.32	$21,608.08	91,546
3/18/2014	Paul Rubin	CMO	Sell	17,649	$6.31	$111,365.19	90,719
3/18/2014	Thomas Klein	Insider	Sell	30,965	$6.32	$195,698.80	93,150
3/17/2014	John Varian	CEO	Sell	10,000	$6.03	$60,300.00	270,035
2/18/2014	John Varian	CEO	Sell	10,000	$7.55	$75,500.00	148,739
2/18/2014	Paul Rubin	CMO	Sell	6,000	$7.55	$45,300.00	3,228
1/21/2014	Paul Rubin	CMO	Sell	6,000	$8.27	$49,620.00	3,228
1/15/2014	John Varian	CEO	Sell	10,000	$8.28	$82,800.00	148,739
1/9/2014	Patrick Md Phd Scannon	VP	Sell	20,000	$8.00	$160,000.00	42,017
12/18/2013	Paul Rubin	CMO	Sell	6,000	$5.67	$34,020.00	3,534
12/16/2013	John Varian	CEO	Sell	10,000	$5.44	$54,400.00	148,739
12/2/2013	Patrick Md Phd Scannon	VP	Sell	20,000	$6.00	$120,000.00	42,017
11/27/2013	Paul Rubin	CMO	Sell	4,696	$4.54	$21,319.84	3,534
11/18/2013	Paul Rubin	CMO	Sell	1,304	$4.08	$5,320.32	3,534
11/15/2013	John Varian	CEO	Sell	64,932	$3.95	$256,481.40	148,739
10/15/2013	John Varian	CEO	Sell	10,000	$4.60	$46,000.00	103,006
9/18/2013	Paul Rubin	CMO	Sell	6,000	$4.53	$27,180.00	8,329
9/16/2013	John Varian	CEO	Sell	10,000	$4.59	$45,900.00	103,006
8/19/2013	Bros. Advisors Lp Baker	Director	Buy	2,757,791	$3.62	$9,983,203.42
8/19/2013	Paul Rubin	CMO	Sell	6,000	$3.74	$22,440.00	14,329
8/15/2013	John Varian	CEO	Sell	61,647	$3.87	$238,573.89	103,006
8/14/2013	Fred Kurland	CFO	Sell	7,498	$3.86	$28,942.28	11,820
8/14/2013	Patrick Md Phd Scannon	VP	Sell	6,002	$3.86	$23,167.72	27,711
8/14/2013	Paul Rubin	CMO	Sell	10,520	$3.86	$40,607.20	20,329
7/18/2013	Paul D Rubin	CMO	Sell	6,000	$4.71	$28,260.00
7/15/2013	John Varian	CEO	Sell	10,000	$4.81	$48,100.00
5/29/2013	Paul D Rubin	CMO	Sell	1,797	$4.16	$7,475.52
5/20/2013	Paul D Rubin	CMO	Sell	6,000	$0.54	$3,240.00
11/14/2012	Fred Kurland	CFO	Sell	9,111	$2.56	$23,324.16
11/14/2012	John Varian	CEO	Sell	40,587	$2.56	$103,902.72
11/14/2012	Patrick J Md Phd Scannon	EVP	Sell	8,773	$2.56	$22,458.88
10/29/2012	Julian Baker	Director	Buy	4,722,666	$3.00	$14,167,998.00

(Data available from 1/1/2013 forward)

XOMA (NASDAQ XOMA) News Headlines

Source:

Date	Headline
	XOMA (XOMA) Upgraded by ValuEngine to Sell www.americanbankingnews.com - April 19 at 11:31 AM
	Validea's Top Five Healthcare Stocks Based On David Dreman - 4/15/2018 www.nasdaq.com - April 16 at 9:52 AM
	XOMA (XOMA) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow seekingalpha.com - April 12 at 10:39 AM
	XOMA (XOMA) Downgraded to D at TheStreet www.americanbankingnews.com - April 10 at 7:31 AM
	XOMA (XOMA) Raised to "Outperform" at Wedbush www.americanbankingnews.com - April 9 at 12:44 PM
	$3.69 Million in Sales Expected for XOMA Co. (XOMA) This Quarter www.americanbankingnews.com - April 8 at 2:26 AM
	XOMA (XOMA) Receives Hold Rating from Zacks Investment Research www.americanbankingnews.com - April 7 at 4:26 PM
	-$0.52 EPS Expected for XOMA Co. (XOMA) This Quarter www.americanbankingnews.com - April 6 at 5:10 PM
	Form 8-K XOMA Corp For: Mar 30 www.streetinsider.com - April 5 at 8:39 AM
	XOMA to Present at the H.C. Wainwright Global Life Sciences Conference feeds.benzinga.com - April 3 at 7:51 AM
	XOMA (XOMA) Receives Buy Rating from HC Wainwright www.americanbankingnews.com - April 1 at 3:10 PM
	Osteoarthritis Market Spotlight: 2018-2028 - Prevelent Cases Expected to Rise from 301 Mn in 2016, to 352 Mn by 2025 globenewswire.com - March 29 at 4:13 PM
	Osteoarthritis Market Spotlight: 2018-2028 - Key Pipeline and Marketed Drugs, Clinical Trials, Upcoming and ... www.prnewswire.com - March 29 at 4:13 PM
	LakePharma Appoints David Boyle To Chief Financial Officer www.prnewswire.com - March 26 at 4:19 PM
	Analysts Anticipate XOMA Co. (XOMA) Will Post Quarterly Sales of $3.69 Million www.americanbankingnews.com - March 22 at 2:52 AM
	XOMA Co. (XOMA) Expected to Announce Earnings of -$0.52 Per Share www.americanbankingnews.com - March 20 at 7:10 PM
	XOMA (XOMA) Stock Rating Lowered by Zacks Investment Research www.americanbankingnews.com - March 17 at 10:31 AM
	Q1 2018 Earnings Estimate for XOMA Co. Issued By Wedbush (XOMA) www.americanbankingnews.com - March 16 at 7:34 AM
	XOMA (XOMA) Rating Increased to Hold at ValuEngine www.americanbankingnews.com - March 10 at 7:42 PM
	XOMA (XOMA) Downgraded by Zacks Investment Research www.americanbankingnews.com - March 9 at 9:02 PM
	XOMA (XOMA) Given a $49.00 Price Target at HC Wainwright www.americanbankingnews.com - March 9 at 6:56 PM
	XOMA Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update finance.yahoo.com - March 8 at 11:05 AM
	XOMA (XOMA) Announces Quarterly Earnings Results, Beats Expectations By $0.19 EPS www.americanbankingnews.com - March 8 at 9:47 AM
	XOMA to Present at the Cowen and Company 38th Annual Health Care Conference finance.yahoo.com - March 5 at 10:51 AM
	$4.12 Million in Sales Expected for XOMA Co. (XOMA) This Quarter www.americanbankingnews.com - March 5 at 4:18 AM
	Bogle Investment Management L P DE Takes $3.66 Million Position in XOMA Co. (XOMA) www.americanbankingnews.com - March 4 at 4:58 AM
	Zacks: Brokerages Anticipate XOMA Co. (XOMA) Will Post Earnings of -$0.52 Per Share www.americanbankingnews.com - March 3 at 4:04 PM
	XOMA (XOMA) Lowered to Hold at Zacks Investment Research www.americanbankingnews.com - February 21 at 2:11 PM
	FDA Grants Agios' (AGIO) Leukemia Candidate Priority Review finance.yahoo.com - February 16 at 4:13 PM
	Zacks: Brokerages Anticipate XOMA Co. (XOMA) to Post -$0.52 EPS www.americanbankingnews.com - February 14 at 9:06 PM
	Cambridge biotech Enumeral files for bankruptcy, sells cancer drugs - Boston Business Journal www.bizjournals.com - February 6 at 3:21 PM
	Theravance's NDA for COPD Candidate Gets FDA Acceptance finance.yahoo.com - January 31 at 6:11 AM
	XOMA (XOMA) versus Osiris Therapeutics (OSIR) Critical Survey www.americanbankingnews.com - January 30 at 7:12 PM
	East Bay drug maker soars 700 percent on Wall Street with plan to NOT make drugs - San Francisco Business Times www.bizjournals.com - January 25 at 3:21 PM
	East Bay drug maker soars 700 percent on Wall Street with plan to NOT make drugs finance.yahoo.com - January 25 at 3:21 PM
	XOMA Co. (XOMA) Receives Average Recommendation of "Buy" from Brokerages www.americanbankingnews.com - January 23 at 5:36 AM
	XOMA (XOMA) Earns "Buy" Rating from HC Wainwright www.americanbankingnews.com - January 21 at 11:38 PM
	XOMA Co. (XOMA) Expected to Post Quarterly Sales of $4.12 Million www.americanbankingnews.com - January 14 at 3:38 PM
	It was a banner year for stocks, but not everyone shared in the wealth www.bizjournals.com - January 11 at 4:32 PM
	It was a banner year for stocks, but not everyone shared in the wealth. finance.yahoo.com - January 8 at 4:32 PM
	XOMA Strengthens Leadership Team with Appointments of Chief Business Officer and General Counsel finance.yahoo.com - January 8 at 10:36 AM
	It was a banner year for stocks, but not everyone shared in the wealth. Here's how Pittsburgh's public companies fared. www.bizjournals.com - January 7 at 12:31 PM
	Anika Therapeutics Receives FDA Nod for Bone Repair Therapy finance.yahoo.com - January 3 at 9:45 AM
	XOMA Co. (XOMA) Receives Consensus Rating of "Buy" from Brokerages www.americanbankingnews.com - December 29 at 7:02 AM
	Zacks: Analysts Expect XOMA Co. (XOMA) Will Announce Quarterly Sales of $4.12 Million www.americanbankingnews.com - December 28 at 6:32 PM
	ETFs with exposure to XOMA Corp. : December 27, 2017 finance.yahoo.com - December 27 at 1:04 PM
	Zacks: Analysts Anticipate XOMA Co. (XOMA) Will Post Earnings of -$0.52 Per Share www.americanbankingnews.com - December 26 at 11:28 AM
	Head to Head Survey: XOMA (XOMA) versus SIGA Technologies (SIGA) www.americanbankingnews.com - December 24 at 11:28 AM
	4 Biotech Stocks That More Than Doubled This Year - Nasdaq www.nasdaq.com - December 22 at 6:35 PM
	Brokers Set Expectations for XOMA Co.'s Q1 2018 Earnings (XOMA) www.americanbankingnews.com - December 21 at 11:28 AM

XOMA (NASDAQ:XOMA) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

XOMA (NASDAQ:XOMA) Income Statement, Balance Sheet and Cash Flow Statement

XOMA (NASDAQ XOMA) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff